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lthough the diagnosis and treatment of febrile neutrope-
ia episodes have improved signiﬁcantly over the past two
ecades, sepsis is still a major cause of mortality and morbid-
ty in patients undergoing chemotherapy regimens that cause
ntensive myelosuppression.1–4 Even in institutions where
arly initiation of antibiotic therapy and advances in sup-
ortive measures have signiﬁcantly reduced the mortality
ssociated with infections, there is great concern about the
orbidity related to these complications.5 Other important
spects to be considered are the high costs associated with
reatment and impaired quality of life of the patients and
heir family, attributable to the need for prolonged or repeated
ospitalizations.6
Therefore, it is extremely important to develop risk-
tratiﬁcation models that can predict the following conditions
arly, that is, at admission or within 48 h of evaluation: (1)
hildren at low risk for developing severe infections who can
ave a reduced intensity of antibiotic therapy and/or a shorter
ospital stay; and (2) children at high risk of developing com-
lications and death who need more  aggressive therapeutic
easures.3,7Although their use is well established in adult patients,
here is still no consensus on scores and strategies for
redicting the risk for infection and complications in children
ith cancer who  present with febrile neutropenia.7 The use
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eserved.of reliable and reproducible scores would allow the identiﬁca-
tion of patients who could beneﬁt from the de-escalation of
intravenous antibiotic therapy to oral administration, would
help to identify the best time for this change in procedure,
and would also contribute to safe decision-making about the
place of treatment – hospital or home.3,7
The results of research on these predictive models rein-
force the importance of developing instruments designed
for the pediatric population, including parameters that can
be easily measured. However, there is great variability in
the methods adopted for assessments, and they are often
based only on clinical data, without sufﬁcient discrimina-
tory power.3,7,8 The elements used in the composition of
these scores include patient-related factors (such as age,
type of cancer, and status of the underlying disease), param-
eters referring to the treatment followed, the presence of
clinical complications (hemodynamic or respiratory insta-
bility, high fever) and laboratory ﬁndings suggestive of
myelosuppression.7,8
In order to move forward and deﬁne parameters for
these predictive models, serum biomarker studies seem to
6,7:395–9.
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becoming more  important. The biomarkers that are most
frequently evaluated and appear to have a greater discrim-
inatory power are the following: C-reactive protein (CRP),
procalcitonin (PCT), interleukin 6, and interleukin 8.6
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In a systematic review and meta-analysis carried out by
Hauesler et al., a marked heterogeneity was found among the
37 studies selected with regard to the diagnosis of the patients
included (hematologic malignancies or solid tumors), the def-
inition of febrile neutropenia, and the outcomes evaluated
(severe sepsis, severe inﬂammatory response syndrome, or
admission to an intensive care unit). The ﬁndings of this study
suggest a greater discrimination power of PCT when compared
to CRP. However, these authors emphasized that the hetero-
geneity of the studies complicates comparisons and prevented
them from reaching deﬁnitive conclusions, which limits the
clinical application of the results.6
Barbosa et al. conducted a study to determine whether
the levels of CD64, a surface marker expressed by activated
neutrophils, could be used as a predictor of positive cultures
in children with febrile neutropenia episodes. Although this
biomarker has been considered promising in studies con-
ducted with adults and newborns, the results obtained by the
Brazilian researchers did not identify CD64 as a biomarker that
can be used to identify febrile neutropenia patients with a high
risk for developing severe infections. The limitations of this
study are similar to those previously described in the litera-
ture, and, as highlighted by the researchers, it is important
to conduct a complementary investigation before reaching
deﬁnitive conclusions.9
It is clear that many  questions need to be answered before
reaching a consensus on the clinical relevance of biomark-
ers in the management of children with febrile neutropenia,
either to guide immediate measures or to assist in the moni-
toring and evaluation of the response to the treatment. Despite
promising evidence, there is still the need for consistent and
reproducible studies to validate the use of these tests and
demonstrate that they can be complementary to evaluations
based on traditional clinical criteria.6,9Conﬂicts  of  interest
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